EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Clinical trials for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS explained in plain language.
Never miss a new study
Get alerted when new EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS trials appear
Sign up with your email to follow new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New study tracks Nucala's Long-Term impact on rare inflammatory disease
Disease control CompletedThis study followed about 300 people with EGPA (a rare disease causing inflammation in blood vessels) who were treated with Nucala injections for up to 2 years. Researchers monitored side effects, how well the drug controlled symptoms, and how long it took for the disease to flar…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug MT-2990 tested in rare blood vessel disease
Disease control CompletedThis early study looked at a new drug, MT-2990, in 5 people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal was to see if the drug is safe and how it affects disease activity. Researchers measured changes in symptoms, imagin…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE1 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Statin trial targets hidden heart risk in vasculitis patients
Disease control CompletedThis study tested whether rosuvastatin, a common cholesterol-lowering drug, could reduce early signs of artery hardening in 121 people with ANCA-associated vasculitis. Participants were in remission and received either rosuvastatin or a placebo for up to 2 years. The goal was to …
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Rituximab vs. azathioprine: which drug better prevents EGPA flares?
Disease control CompletedThis study tested whether rituximab (given as an infusion every 6 months) is better than azathioprine (daily pills) at keeping eosinophilic granulomatosis with polyangiitis (EGPA) in remission. 98 adults with newly diagnosed or relapsing EGPA who had already achieved remission to…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Scientists probe immune cells to unlock vasculitis mysteries
Knowledge-focused CompletedThis study looked at how certain immune cells, called neutrophils, behave in people with granulomatosis with polyangiitis (GPA), a rare blood vessel inflammation disease. Researchers collected blood samples from 93 participants, including patients with GPA and other related condi…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:35 UTC